lovastatin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors 1612 75330-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lovastatin
  • lostatin
  • mevacor
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
  • Molecular weight: 404.55
  • Formula: C24H36O5
  • CLOGP: 4.08
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.83
  • ALOGS: -4.22
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
45 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.29 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 31, 1987 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 47.23 12.57 122 17644 124197 50463161
Cardiac failure congestive 46.62 12.57 96 17670 84286 50503072
Rhabdomyolysis 45.37 12.57 62 17704 38965 50548393
Drug hypersensitivity 42.10 12.57 187 17579 250823 50336535
Blood glucose increased 38.05 12.57 80 17686 71244 50516114
Atrial fibrillation 30.85 12.57 92 17674 101653 50485705
Synovitis 29.99 12.57 4 17762 123861 50463497
Exposure during pregnancy 29.08 12.57 4 17762 121011 50466347
Muscle spasms 28.60 12.57 103 17663 125450 50461908
Infusion related reaction 28.37 12.57 12 17754 169545 50417813
Treatment failure 27.85 12.57 7 17759 137630 50449728
Systemic lupus erythematosus 26.86 12.57 8 17758 140614 50446744
Glossodynia 25.14 12.57 5 17761 115564 50471794
Rheumatoid arthritis 24.57 12.57 21 17745 202529 50384829
Myocardial infarction 22.84 12.57 76 17690 88951 50498407
Wound 22.14 12.57 5 17761 105789 50481569
Asthenia 22.06 12.57 189 17577 318853 50268505
Off label use 21.95 12.57 89 17677 474337 50113021
Retroperitoneal oedema 20.50 12.57 4 17762 21 50587337
Myopathy 19.82 12.57 20 17746 9119 50578239
General physical health deterioration 19.53 12.57 13 17753 142421 50444937
Dehydration 19.35 12.57 105 17661 152344 50435014
Cerebrovascular accident 19.32 12.57 75 17691 94605 50492753
Coronary artery disease 19.03 12.57 36 17730 29690 50557668
Chronic obstructive pulmonary disease 18.80 12.57 51 17715 53384 50533974
Febrile neutropenia 17.85 12.57 6 17760 97661 50489697
Lower respiratory tract infection 17.14 12.57 6 17760 95195 50492163
Alopecia 17.04 12.57 38 17728 245009 50342349
Amyotrophic lateral sclerosis 16.87 12.57 8 17758 1059 50586299
Pyrexia 16.53 12.57 73 17693 380130 50207228
Drug intolerance 16.05 12.57 33 17733 219071 50368287
Dizziness 15.64 12.57 188 17578 346181 50241177
Psoriasis 15.18 12.57 56 17710 68944 50518414
Feeling abnormal 14.96 12.57 85 17681 125407 50461951
Product dose omission issue 14.90 12.57 113 17653 183725 50403633
Product quality issue 14.61 12.57 33 17733 30825 50556533
Product use issue 14.21 12.57 19 17747 149456 50437902
C-reactive protein increased 14.19 12.57 3 17763 66471 50520887
Hepatic enzyme increased 13.53 12.57 17 17749 137363 50449995
Nausea 13.47 12.57 333 17433 705065 49882293
Product use in unapproved indication 12.86 12.57 13 17753 115806 50471552
Chest pain 12.83 12.57 106 17660 176776 50410582
Gait disturbance 12.60 12.57 93 17673 149912 50437446
Pulmonary arterial pressure increased 12.59 12.57 10 17756 3338 50584020

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myasthenic syndrome 38.26 13.51 12 13427 395 29560693
Rhabdomyolysis 36.04 13.51 83 13356 60725 29500363
Cardiac failure congestive 31.39 13.51 91 13348 76490 29484598
Neck mass 29.17 13.51 14 13425 1467 29559621
Drug abuse 23.52 13.51 4 13435 79879 29481209
Myalgia 23.03 13.51 80 13359 73939 29487149
Back disorder 22.67 13.51 20 13419 5953 29555135
Diverticulum 21.67 13.51 20 13419 6312 29554776
Cerebrovascular accident 21.28 13.51 80 13359 76831 29484257
Sleep inertia 20.36 13.51 4 13435 16 29561072
Hand deformity 19.18 13.51 12 13427 2118 29558970
Febrile neutropenia 18.96 13.51 14 13425 112226 29448862
Thrombocytosis 18.58 13.51 14 13425 3339 29557749
Blood creatine phosphokinase increased 18.30 13.51 50 13389 40594 29520494
Anxiety 18.24 13.51 82 13357 85283 29475805
Injury 17.23 13.51 31 13408 19015 29542073
Asthenia 16.70 13.51 160 13279 215090 29345998
Myopathy 16.35 13.51 22 13417 10511 29550577
Pyrexia 15.31 13.51 73 13366 287549 29273539
Off label use 15.06 13.51 78 13361 300722 29260366
Pinguecula 14.41 13.51 3 13436 17 29561071
Atrial fibrillation 14.01 13.51 89 13350 105557 29455531
Acquired haemophilia 13.72 13.51 7 13432 836 29560252
Gross motor delay 13.59 13.51 5 13434 269 29560819

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 84.74 11.96 134 23595 91592 64383411
Cardiac failure congestive 73.67 11.96 154 23575 130426 64344577
Myalgia 46.41 11.96 146 23583 158471 64316532
Blood glucose increased 41.22 11.96 103 23626 97970 64377033
Myocardial infarction 37.43 11.96 140 23589 165681 64309322
Drug abuse 37.38 11.96 3 23726 132371 64342632
Asthenia 36.08 11.96 275 23454 427769 64047234
Myopathy 35.60 11.96 38 23691 17642 64457361
Myasthenic syndrome 35.32 11.96 12 23717 633 64474370
Drug hypersensitivity 32.59 11.96 173 23556 237642 64237361
Atrial fibrillation 31.83 11.96 136 23593 170953 64304050
Cerebrovascular accident 30.08 11.96 115 23614 137468 64337535
Infusion related reaction 29.14 11.96 12 23717 164455 64310548
Febrile neutropenia 28.27 11.96 17 23712 187640 64287363
Contraindicated product administered 26.52 11.96 4 23725 107825 64367178
Off label use 25.00 11.96 134 23595 632672 63842331
Coronary artery disease 24.89 11.96 63 23666 60370 64414633
Treatment failure 23.30 11.96 7 23722 116809 64358194
Pyrexia 21.66 11.96 119 23610 558525 63916478
General physical health deterioration 21.64 11.96 26 23703 204399 64270604
Back disorder 21.05 11.96 22 23707 9968 64465035
Intentional overdose 20.66 11.96 4 23725 89940 64385063
Sleep inertia 20.64 11.96 4 23725 19 64474984
Retroperitoneal oedema 20.31 11.96 4 23725 21 64474982
Product use in unapproved indication 20.30 11.96 21 23708 176597 64298406
Neck mass 18.88 11.96 14 23715 4030 64470973
Interstitial lung disease 17.52 11.96 7 23722 97725 64377278
Myositis 16.61 11.96 25 23704 16352 64458651
Dehydration 16.41 11.96 136 23593 216627 64258376
Muscle spasms 16.25 11.96 98 23631 140925 64334078
Mental status changes 15.79 11.96 54 23675 61108 64413895
Cardiovascular disorder 15.76 11.96 24 23705 15857 64459146
Product quality issue 15.46 11.96 34 23695 29765 64445238
Blood creatine phosphokinase increased 15.38 11.96 52 23677 58506 64416497
Lower respiratory tract infection 15.06 11.96 8 23721 94606 64380397
Diverticulum 14.61 11.96 21 23708 13177 64461826
Chronic obstructive pulmonary disease 14.39 11.96 58 23671 70990 64404013
Product dose omission issue 14.11 11.96 121 23608 194626 64280377
Pericarditis 13.90 11.96 3 23726 62513 64412490
Pain in extremity 13.70 11.96 171 23558 302914 64172089
Feeling abnormal 13.63 11.96 90 23639 133512 64341491
Rheumatoid arthritis 13.40 11.96 25 23704 164269 64310734
Amyotrophic lateral sclerosis 13.24 11.96 8 23721 1642 64473361
Fatigue 12.52 11.96 362 23367 748368 63726635
International normalised ratio increased 12.51 11.96 60 23669 79107 64395896
Chronic kidney disease 12.30 11.96 48 23681 57871 64417132
Plasma cell myeloma 12.18 11.96 41 23688 46034 64428969

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AA02 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
HMG CoA reductase inhibitors
ATC C10BA01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
FDA MoA N0000000121 Hydroxymethylglutaryl-CoA Reductase Inhibitors
FDA EPC N0000175589 HMG-CoA Reductase Inhibitor
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35821 anticholesteremic drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:76956 Aspergillus metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Arteriosclerotic vascular disease indication 72092001
Hypoalphalipoproteinemia indication 190785000
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006
Myocardial Reinfarction Prevention indication
Slow Progression of Coronary Artery Disease indication
Primary Prevention of Coronary Heart Disease indication
Myocardial Infarction Prevention indication
Cerebrovascular accident off-label use 230690007
Prevention of Transient Ischemic Attacks off-label use
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Gout contraindication 90560007 DOID:13189
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Hemorrhagic cerebral infarction contraindication 230706003
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Traumatic injury contraindication 417746004
Uncontrolled Epilepsy contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR IC50 7.67 WOMBAT-PK CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 5.10 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.81 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor AGONIST EC50 6 IUPHAR
Hydroxycarboxylic acid receptor 2 GPCR IC50 7.30 WOMBAT-PK
Hydroxycarboxylic acid receptor 3 GPCR IC50 6.53 WOMBAT-PK
Histone deacetylase 2 Enzyme IC50 4.59 CHEMBL
Histone deacetylase 1 Enzyme IC50 4.92 CHEMBL
Histone deacetylase 6 Enzyme IC50 4.79 CHEMBL
Substance-K receptor GPCR Ki 5.03 DRUG MATRIX
Leukocyte adhesion glycoprotein LFA-1 alpha Adhesion Kd 4.89 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.06 DRUG MATRIX
Androgen receptor Transcription factor Ki 4.70 DRUG MATRIX
Acetylcholinesterase Enzyme Ki 5.57 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 8.52 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 7.57 CHEMBL
Cholinesterase Enzyme Ki 5.96 CHEMBL
Acyl-CoA:cholesterol acyltransferase Enzyme IC50 4.77 CHEMBL

External reference:

IDSource
4019482 VUID
N0000147602 NUI
D00359 KEGG_DRUG
4019482 VANDF
C0024027 UMLSCUI
CHEBI:40303 CHEBI
803 PDB_CHEM_ID
CHEMBL503 ChEMBL_ID
D008148 MESH_DESCRIPTOR_UI
DB00227 DRUGBANK_ID
53232 PUBCHEM_CID
2739 IUPHAR_LIGAND_ID
6074 INN_ID
9LHU78OQFD UNII
224938 RXNORM
1105 MMSL
42628 MMSL
4998 MMSL
d00280 MMSL
002063 NDDF
386024001 SNOMEDCT_US
96303004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0576 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0926 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0928 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0070 TABLET 10 mg ORAL ANDA 18 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0072 TABLET 20 mg ORAL ANDA 18 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0074 TABLET 40 mg ORAL ANDA 18 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8151 TABLET 20 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8152 TABLET 40 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-235 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-241 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-242 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin Human Prescription Drug Label 1 10544-246 TABLET 20 mg ORAL ANDA 19 sections
LOVASTATIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-311 TABLET 10 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-534 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-535 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-536 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-547 TABLET 10 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-548 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-549 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-025 TABLET 40 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-028 TABLET 20 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-106 TABLET 10 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-493 TABLET 10 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-548 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-548 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-692 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-939 TABLET 40 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-983 TABLET 20 mg ORAL ANDA 22 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43353-763 TABLET 40 mg ORAL ANDA 21 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43353-995 TABLET 40 mg ORAL ANDA 22 sections